All Stories

  1. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis
  2. Microscale Thermophoresis and Docking Studies Suggest Lapachol and Auraptene are Ligands of IDO1
  3. Opportunities and challenges in drug discovery targeting metabotropic glutamate receptor 4
  4. Immunotherapy… a pursuit race to tomorrow's medicines
  5. Binding properties of different categories of IDO1 inhibitors: a microscale thermophoresis study
  6. 4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)
  7. Integrating multicomponent flow synthesis and computational approaches for the generation of a tetrahydroquinoline compound based library
  8. The Janus-faced nature of IDO1 in infectious diseases: challenges and therapeutic opportunities
  9. Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors
  10. Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
  11. Very-long-chain fatty acid sphingomyelin in nuclear lipid microdomains of hepatocytes and hepatoma cells: can the exchange from C24:0 to C16:0 affect signal proteins and vitamin D receptor?
  12. Pharmacophore-Based Virtual Screening to Discover New Active Compounds for Human Choline Kinase α1
  13. VERY LONG CHAIN FATTY ACID SPHINGOMYELIN IN NUCLEAR LIPID MICRODOMAINS OF HEPATOCYTES AND HEPATOMA CELLS: CAN THE EXCHANGE FROM C24:0 TO C16:0 AFFECT SIGNAL PROTEINS AND VITAMIN D RECEPTOR?
  14. Pharmacophore-based virtual screening to discover new active compounds for human choline kinase alpha1.
  15. Choline Kinase Active Site Provides Features for Designing Versatile Inhibitors
  16. Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
  17. Bile Acid Derivatives as Ligands of the Farnesoid X Receptor: Molecular Determinants for Bile Acid Binding and Receptor Modulation
  18. Ligand Binding and Functional Selectivity of l-Tryptophan Metabolites at the Mouse Aryl Hydrocarbon Receptor (mAhR)
  19. Scaffold hopping approach on the route to selective tankyrase inhibitors
  20. AhR-Mediated, Non-Genomic Modulation of IDO1 Function
  21. Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy
  22. Targeting glucocorticoid side effects: selective glucocorticoid receptor modulator or glucocorticoid-induced leucine zipper? A perspective
  23. Aryl hydrocarbon receptor control of a disease tolerance defence pathway
  24. Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment
  25. Mo1915 Novel Wnt-Targeted Therapy Inhibitors for Hepatocellular Carcinoma
  26. Design, Synthesis, Crystallographic Studies, and Preliminary Biological Appraisal of New Substituted Triazolo[4,3- b ]pyridazin-8-amine Derivatives as Tankyrase Inhibitors
  27. Conformational properties of cholic acid, a lead compound at the crossroads of bile acid inspired drug discovery
  28. From Polypharmacology to Target Specificity: The Case of PARP Inhibitors
  29. Probing the Binding Site of Bile Acids in TGR5
  30. Exploring the effect of PARP-1 flexibility in docking studies
  31. Synthesis and Quantitative Structure-Property Relationships of Side Chain-Modified Hyodeoxycholic Acid Derivatives
  32. PARP inhibitors: polypharmacology versus selective inhibition
  33. Navigations of chemical space to further the understanding of polypharmacology in human nuclear receptors
  34. Chiral mobile phase in ligand-exchange chromatography of amino acids: Exploring the copper(II) salt anion effect with a computational approach
  35. Patented TGR5 modulators: a review (2006 – present)
  36. Fitting the complexity of GPCRs modulation into simple hypotheses of ligand design
  37. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists
  38. Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators
  39. Identification by Virtual Screening and In Vitro Testing of Human DOPA Decarboxylase Inhibitors
  40. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
  41. From Molecular Docking to 3D-Quantitative Structure-Activity Relationships (3D-QSAR): Insights into the Binding Mode of 5-Lipoxygenase Inhibitors
  42. Chapter 10. TGR5 Agonists in Development
  43. Protective Effects of Commiphora erythraea Resin Constituents Against Cellular Oxidative Damage
  44. Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine
  45. Mechanistic Aspects and Applications of Chiral Ligand-Exchange Chromatography
  46. Divergent and stereoselective synthesis of dafachronic acids
  47. Alternative strategies for targeting mouse double minute 2 activity with small molecules: novel patents on the horizon?
  48. Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
  49. Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ
  50. Computational studies for the elucidation of the enantiomer elution order of amino acids in chiral ligand-exchange chromatography
  51. Insights into the binding mode and mechanism of action of some atypical retinoids as ligands of the small heterodimer partner (SHP)
  52. Molecular Interaction Fields and 3D-QSAR Studies of p53−MDM2 Inhibitors Suggest Additional Features of Ligand−Target Interaction
  53. Puzzling over MDM4–p53 network
  54. Novel Polymorphisms of Nuclear Receptor SHP Associated with Functional and Structural Changes
  55. ChemInform Abstract: Metabotropic Glutamate Receptors: Structure and New Subtype-Selective Ligands
  56. ChemInform Abstract: Design, Synthesis and Preliminary Evaluation of Novel 3′-Substituted Carboxycyclopropylglycines (XIV) as Antagonists at Group 2 Metabotropic Glutamate Receptors.
  57. Chiral ligand-exchange separation and resolution of extremely rigid glutamate analogs: 1-aminospiro[2.2]pentyl-1,4-dicarboxylic acids
  58. Discovery of 6α-Ethyl-23( S )-methylcholic Acid ( S -EMCA, INT-777) as a Potent and Selective Agonist for the TGR5 Receptor, a Novel Target for Diabesity
  59. Quantum mechanics/molecular mechanics (QM/MM) modeling of the irreversible transamination of l-kynurenine to kynurenic acid: The round dance of kynurenine aminotransferase II
  60. Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition
  61. Derived chromatographic indices as effective tools to study the self-aggregation process of bile acids
  62. Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif
  63. Mapping Human Metabolic Pathways in the Small Molecule Chemical Space
  64. TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
  65. Bulky 1,4-benzoxazine derivatives with antifungal activity
  66. MDM2/MDMX inhibitor peptide: WO2008106507
  67. Poly(ADP-ribose) Catabolism Triggers AMP-dependent Mitochondrial Energy Failure
  68. Charting the Chemical Space of Target Sites: Insights into the Binding Modes of Amine and Amidine Groups
  69. The effect of the copper(II) salt anion in the Chiral Ligand-Exchange Chromatography of amino acids
  70. ChemInform Abstract: Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition.
  71. Design, synthesis and biological evaluation of novel bicyclo[1.1.1]pentane-based ω-acidic amino acids as glutamate receptors ligands
  72. ChemInform Abstract: Molecular Field Analysis and 3D-Quantitative Structure-Activity Relationship Study (MFA 3D-QSAR) Unveil Novel Features of Bile Acid Recognition at TGR5.
  73. Cysteine-based chiral selectors for the ligand-exchange separation of amino acids☆
  74. Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition
  75. Adamantyl-Substituted Retinoid-Derived Molecules That Interact with the Orphan Nuclear Receptor Small Heterodimer Partner: Effects of Replacing the 1-Adamantyl or Hydroxyl Group on Inhibition of Cancer Cell Growth, Induction of Cancer Cell Apoptosis, a...
  76. Molecular Field Analysis and 3D-Quantitative Structure−Activity Relationship Study (MFA 3D-QSAR) Unveil Novel Features of Bile Acid Recognition at TGR5
  77. Sequence Variants in Kynurenine Aminotransferase II (KAT II) Orthologs Determine Different Potencies of the InhibitorS-ESBA
  78. Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure−Activity Relationships, and Molecular Modeling Studies
  79. Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease
  80. Descriptive structure-separation relationship studies in chiral ligand-exchange chromatography
  81. Novel Potent and Selective Bile Acid Derivatives as TGR5 Agonists: Biological Screening, Structure−Activity Relationships, and Molecular Modeling Studies
  82. S‐Trityl‐(R)‐cysteine, a powerful chiral selector for the analytical and preparative ligand‐exchange chromatography of amino acids
  83. Exploring the other side of biologically relevant chemical space: Insights into carboxylic, sulfonic and phosphonic acid bioisosteric relationships
  84. Nongenomic Actions of Bile Acids. Synthesis and Preliminary Characterization of 23- and 6,23-Alkyl-Substituted Bile Acid Derivatives as Selective Modulators for the G-Protein Coupled Receptor TGR5
  85. Synthesis, Molecular Modeling Studies, and Preliminary Pharmacological Characterization of All Possible 2-(2‘-Sulfonocyclopropyl)glycine Stereoisomers as Conformationally ConstrainedL-Homocysteic Acid Analogs
  86. Oxime and Oxime Ether Derivatives of 1,4-Benzothiazine Related to Oxiconazole
  87. Molecular docking and spatial coarse graining simulations as tools to investigate substrate recognition, enhancer binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO)
  88. Synthesis, docking studies and anti-inflammatory activity of 4,5,6,7-tetrahydro-2H-indazole derivatives
  89. (S)-(–)-α,α-Di(2-naphthyl)-2-pyrrolidinemethanol, a useful tool to study the recognition mechanism in chiral ligand-exchange chromatography
  90. Glucocorticoid-induced leucine zipper (GILZ)/NF- B interaction: role of GILZ homo-dimerization and C-terminal domain
  91. Pharmacophore model for bile acids recognition by the FPR receptor
  92. Novel ketoconazole analogues based on the replacement of 2,4-dichlorophenyl group with 1,4-benzothiazine moiety: Design, synthesis, and microbiological evaluation
  93. Synthesis and Preliminary Biological Evaluation of 2′-Substituted 2-(3′-Carboxybicyclo[1.1.1]pentyl)glycine Derivatives as Group I Selective Metabotropic Glutamate Receptor Ligands
  94. Unveiling hidden features of orphan nuclear receptors: The case of the small heterodimer partner (SHP)
  95. Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinoma
  96. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAFV599Ins)
  97. Dynamic ligand-exchange chiral stationary phase from S-benzyl-(R)-cysteine
  98. Design, Synthesis, and Microbiological Evaluation of New Candida albicans CYP51 Inhibitors
  99. Is Antagonism of E / Z -Guggulsterone at the Farnesoid X Receptor Mediated by a Noncanonical Binding Site? A Molecular Modeling Study
  100. Molecular Dynamics Simulation of the Ligand Binding Domain of Farnesoid X Receptor. Insights into Helix-12 Stability and Coactivator Peptide Stabilization in Response to Agonist Binding
  101. Docking studies on PARP-1 inhibitors: insights into the role of a binding pocket water molecule
  102. Insights into Phenylalanine Derivatives Recognition of VLA-4 Integrin: From a Pharmacophoric Study to 3D-QSAR and Molecular Docking Analyses.
  103. Homology model of the multidrug transporter LmrA from Lactococcus lactis
  104. Insights into Phenylalanine Derivatives Recognition of VLA-4 Integrin:  From a Pharmacophoric Study to 3D-QSAR and Molecular Docking Analyses
  105. Ligand selectivity and competition between enzymes in silico
  106. Evaluation of the enantiomeric selectivity in the chiral ligand-exchange chromatography of amino acids by a computational model
  107. QSAR Study of Anticonvulsant Negative Allosteric Modulators of the AMPA Receptor
  108. Towards New Neuroprotective Agents: Design and Synthesis of 4H-Thieno[2,3-c]isoquinolin-5-one Derivatives as Potent PARP-1 Inhibitors.
  109. PROPRIEDADES DIELÉTRICAS E TÉRMICAS DE COMPÓSITOS DE BORRACHA NATURAL COM MICA
  110. Rat brain guanosine binding site
  111. Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors
  112. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR)
  113. The role of electrostatic interaction in the molecular recognition of selective agonists to metabotropic glutamate receptors
  114. Binding modes of noncompetitive AMPA antagonists: a computational approach
  115. Modulation of the Kynurine Pathway of Tryptophan Metabolism in Search for Neuroprotective Agents. Focus on Kynurenine-3-Hydroxylase
  116. Glucocorticoid-Induced Leucine Zipper Inhibits the Raf-Extracellular Signal-Regulated Kinase Pathway by Binding to Raf-1
  117. 1,4-Benzothiazine and 1,4-Benzoxazine imidazole derivatives with antifungal activity: A docking study
  118. Spiro[2.2]pentane as a Dissymmetric Scaffold for Conformationally Constrained Analogues of Glutamic Acid:  Focus on Racemic 1-Aminospiro[2.2]pentyl-1,4-dicarboxylic Acids
  119. Structure of metal–carbenoid intermediates derived from the dirhodium(II)tetracarboxylate mediated decomposition of α-diazocarbonyl compounds: a DFT study
  120. Metabotropic glutamate receptors: targets for therapy of cerebral ischaemia
  121. Design, synthesis and preliminary evaluation of novel 3′-Substituted carboxycyclopropylglycines as antagonists at group 2 metabotropic glutamate receptors
  122. Conformational analysis of carboxyphenylglycine (CPG) derivatives: insight into bioactive and bioselective conformations of group-I mGluRs antagonists
  123. Modeling of Poly(ADP-ribose)polymerase (PARP) Inhibitors. Docking of Ligands and Quantitative Structure−Activity Relationship Analysis
  124. QSAR and Molecular Modeling Studies of Baclofen Analogues as GABA B Agonists. Insights into the Role of the Aromatic Moiety in GABA B Binding and Activation
  125. Homology model of the closed, functionally active, form of the amino terminal domain of mGluR1
  126. Metabotropic glutamate receptors: structure and new subtype-selective ligands
  127. Metabotropic glutamate receptors: a structural view point
  128. Metabotropic glutamate receptors: a structural view point
  129. Modeling of Amino-Terminal Domains of Group I Metabotropic Glutamate Receptors:  Structural Motifs Affecting Ligand Selectivity
  130. Pharmacophore Models of Group I and Group II Metabotropic Glutamate Receptor Agonists. Analysis of Conformational, Steric, and Topological Parameters Affecting Potency and Selectivity